Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $17.13 in the prior trading day, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) closed at $15.21, down -11.21%. In other words, the price has decreased by -$11.21 from its previous closing price. On the day, 5.28 million shares were traded. ACAD stock price reached its highest trading level at $17.5 during the session, while it also had its lowest trading level at $15.17.
Ratios:
Our goal is to gain a better understanding of ACAD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.34 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 39.47. For the most recent quarter (mrq), Quick Ratio is recorded 1.86 and its Current Ratio is at 2.04. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 12, 2024, Reiterated its Buy rating but revised its target price to $32 from $36 previously.
On March 12, 2024, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $39 to $25.
On January 30, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $40.Robert W. Baird initiated its Outperform rating on January 30, 2024, with a $40 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 02 ’24 when DAVIS STEPHEN sold 11,427 shares for $16.94 per share. The transaction valued at 193,573 led to the insider holds 155,231 shares of the business.
Schneyer Mark C. sold 3,503 shares of ACAD for $59,341 on May 02 ’24. The EVP, CHIEF FINANCIAL OFFICER now owns 32,053 shares after completing the transaction at $16.94 per share. On May 02 ’24, another insider, Teehan Brendan, who serves as the EVP, COO, HEAD OF COMMERCIAL of the company, sold 3,477 shares for $16.94 each. As a result, the insider received 58,900 and left with 42,133 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 2512737792 and an Enterprise Value of 2401658624. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.09 while its Price-to-Book (P/B) ratio in mrq is 5.41. Its current Enterprise Value per Revenue stands at 2.951 whereas that against EBITDA is 1245.028.
Stock Price History:
The Beta on a monthly basis for ACAD is 0.43, which has changed by -0.19728208 over the last 52 weeks, in comparison to a change of 0.25590587 over the same period for the S&P500. Over the past 52 weeks, ACAD has reached a high of $33.99, while it has fallen to a 52-week low of $16.16. The 50-Day Moving Average of the stock is -18.94%, while the 200-Day Moving Average is calculated to be -36.49%.
Shares Statistics:
The stock has traded on average 1.84M shares per day over the past 3-months and 1585280 shares per day over the last 10 days, according to various share statistics. A total of 164.65M shares are outstanding, with a floating share count of 163.89M. Insiders hold about 0.80% of the company’s shares, while institutions hold 96.69% stake in the company. Shares short for ACAD as of 1713139200 were 11164319 with a Short Ratio of 6.08, compared to 1710460800 on 10630243. Therefore, it implies a Short% of Shares Outstanding of 11164319 and a Short% of Float of 9.1800004.
Earnings Estimates
The dynamic stock of Acadia Pharmaceuticals Inc (ACAD) is currently attracting attention from 20.0 analysts actively involved in rating its market status.On average, analysts expect EPS of $0.19 for the current quarter, with a high estimate of $0.27 and a low estimate of $0.11, while EPS last year was $0.01. The consensus estimate for the next quarter is $0.21, with high estimates of $0.31 and low estimates of $0.13.
Analysts are recommending an EPS of between $0.97 and $0.3 for the fiscal current year, implying an average EPS of $0.64. EPS for the following year is $1.24, with 20.0 analysts recommending between $2.16 and $0.67.
Revenue Estimates
19 analysts predict $241.29M in revenue for the current quarter. It ranges from a high estimate of $253M to a low estimate of $233.3M. As of the current estimate, Acadia Pharmaceuticals Inc’s year-ago sales were $157.81MFor the next quarter, 19 analysts are estimating revenue of $253.87M. There is a high estimate of $265.3M for the next quarter, whereas the lowest estimate is $245.4M.
A total of 20 analysts have provided revenue estimates for ACAD’s current fiscal year. The highest revenue estimate was $983.8M, while the lowest revenue estimate was $940.7M, resulting in an average revenue estimate of $965.51M. In the same quarter a year ago, actual revenue was $726.44MBased on 20 analysts’ estimates, the company’s revenue will be $1.09B in the next fiscal year. The high estimate is $1.2B and the low estimate is $993.2M.
